With the advent of intensive combination chemotherapy programs, the great majority of patients with newly diagnosed hematologic malignancies can be induced into a complete remission status. However, despite initial sensitivity, resistance to chemotherapy with subsequent relapse is the primary cause of treatment failure in these diseases. New strategies to prevent relapse are clearly needed. In previous studies, we have examined immunologic approaches to induce or enhance anti-tumor immunity and have focused on immune modulation with exogenous lymphokines such as IL-2. In patients with solid tumors we demonstrated that relatively low doses of IL- 2 could be safely administered for prolonged periods resulting in the marked increase in the total number of circulating natural killer (NK) cells and NK activity. Similar results have also been found in patients with hematologic malignancies after either autologous or T cell depleted allogeneic BMT. In patients with AML, the use of IL-2 following completion of post-remission intensification appears able to enhance non-specific cytotoxicity against autologous AML cells without excessive systemic toxicity and thus far few relapses have been observed following immunotherapy. Studies proposed ina the next funding period will further extend our examination of the role of il-2 to enhance anti-tumor immunity. We will also begin to examine new approaches to enhance tumor immunity in patients with leukemia or lymphoma using strategies developed in other projects within this program.
The Specific Aims of this project are listed below; 1. To evaluate the systemic administration of cytokines to enhance both specific and nonspecific immunity against autologous leukemia and lymphoma. 1.1 To determine the immunologic effects of prolonged low dose IL-2 infusion and bolus IL-2 infusion when administered to patients with AML in first CR. 1.2 To define the immunologic effects of IL-2 administration following autologous BMT for B cell non-Hodgkin's lymphoma. 1.3 To evaluate the potential use of other cytokines for enhancement of non-specific immunity in vivo in patients with AML and B cell non-Hodgkin's lymphoma. 1.4 To examine the efficacy of humanized anti-CD33 monoclonal antibody in conjunction with IL-2 in patients with relapsed AML. 2. To evaluate new methods for inducing or enhancing autologous anti-tumor immunity in vivo based on the ability to enhance tumor cell expression of costimulatory molecules in vitro. 3. To develop methods for in vitro activation and expansion of autologous leukemia or lymphoma reactive T cells for use in adoptive cellular therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA066996-01A1
Application #
5209413
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Chu, S Haihua; Song, Evelyn J; Chabon, Jonathan R et al. (2018) Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv 2:2478-2490
Sridhar, Radhakrishnan; Takei, Hisashi; Syed, Riyaz et al. (2018) Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP?. Molecules 23:
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Wang, Jinhua; Erazo, Tatiana; Ferguson, Fleur M et al. (2018) Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol 13:2438-2448
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133
Cortes, Jorge E; Douglas Smith, B; Wang, Eunice S et al. (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 93:1301-1310
Cusan, Monica; Cai, Sheng F; Mohammad, Helai P et al. (2018) LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBP?-dependent enhancers in AML. Blood 131:1730-1742
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
DiNardo, Courtney D; Pratz, Keith; Pullarkat, Vinod et al. (2018) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood :
Postalcioglu, Merve; Kim, Haesook T; Obut, Faruk et al. (2018) Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:2344-2353

Showing the most recent 10 out of 376 publications